Equities research analysts expect OptimizeRx Co. (NASDAQ:OPRX) to announce $6.78 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for OptimizeRx’s earnings, with the highest sales estimate coming in at $6.88 million and the lowest estimate coming in at $6.63 million. OptimizeRx reported sales of $5.10 million during the same quarter last year, which indicates a positive year-over-year growth rate of 32.9%. The company is scheduled to announce its next earnings results on Tuesday, August 6th.

According to Zacks, analysts expect that OptimizeRx will report full year sales of $28.66 million for the current financial year, with estimates ranging from $28.45 million to $28.85 million. For the next fiscal year, analysts anticipate that the business will report sales of $37.16 million, with estimates ranging from $37.16 million to $37.17 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for OptimizeRx.

Separately, Zacks Investment Research cut shares of OptimizeRx from a “buy” rating to a “hold” rating in a report on Friday, March 1st. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. OptimizeRx presently has an average rating of “Buy” and an average target price of $19.00.

In related news, major shareholder Awm Investment Company, Inc. sold 21,397 shares of the firm’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $15.05, for a total value of $322,024.85. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

A number of large investors have recently modified their holdings of OPRX. Vanguard Group Inc acquired a new stake in OptimizeRx in the third quarter valued at approximately $5,204,000. BlackRock Inc. acquired a new stake in OptimizeRx during the fourth quarter worth approximately $55,000. Timpani Capital Management LLC raised its holdings in OptimizeRx by 51.5% during the fourth quarter. Timpani Capital Management LLC now owns 108,643 shares of the company’s stock worth $1,192,000 after purchasing an additional 36,949 shares in the last quarter. Northern Trust Corp raised its holdings in OptimizeRx by 71.5% during the fourth quarter. Northern Trust Corp now owns 17,474 shares of the company’s stock worth $192,000 after purchasing an additional 7,283 shares in the last quarter. Finally, Alambic Investment Management L.P. acquired a new stake in OptimizeRx during the fourth quarter worth approximately $289,000. 48.47% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:OPRX traded down $0.12 during mid-day trading on Friday, hitting $15.39. The stock had a trading volume of 57,356 shares, compared to its average volume of 83,194. The stock has a market cap of $187.60 million, a price-to-earnings ratio of 307.80, a price-to-earnings-growth ratio of 1.66 and a beta of 0.94. OptimizeRx has a twelve month low of $7.25 and a twelve month high of $18.39. The company has a quick ratio of 4.02, a current ratio of 4.02 and a debt-to-equity ratio of 0.03.

About OptimizeRx

OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care.

Recommended Story: What is a good dividend yield?

Get a free copy of the Zacks research report on OptimizeRx (OPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for OptimizeRx (NASDAQ:OPRX)

Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.